Everything below concerns Gastric protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States, and in the European Union in January 2008.
Kecap manis: Sweetened soy sauce, which has a thick syrupy consistency and a unique, pronounced, sweet, somewhat treacle-like flavor due to generous addition of palm sugar. Regular soy with brown sugar and a trace of molasses added can substitute. It is by far the most popular type of soy sauce employed in Indonesian cuisine, accounts for an estimated 90 percent of the nation's total soy sauce production. Kecap manis is an important sauce in Indonesian signature dishes, such as nasi goreng, mie goreng, satay, tongseng and semur. Sambal kecap for example is type of sambal dipping sauce of kecap manis with sliced chili, tomato and shallot, a popular dipping sauce for sate kambing (goat meat satay) and ikan bakar (grilled fish/seafood). Since soy sauce is of Chinese origin, kecap asin is also an important seasoning in Chinese Indonesian cuisine. Kecap manis sedang: Medium sweet soy sauce, which has a less thick consistency, is less sweet and has a saltier taste than kecap manis. Kecap asin: Regular soy sauce derived from the Japanese shoyu, but usually more concentrated and thicker, with a darker color and stronger flavor; it can be replaced by Chinese light soy sauce in some recipes. Salty soy sauce was first introduced into Indonesia by Hokkien people so its taste resembles that of Chinese soy sauce. Hakka soy sauce made from black beans is very salty and large productions are mainly made in Bangka Island.
== National Mass Spectrometry Service == A grant of £670,000 was awarded in 1985 by the then Science and Engineering Research Council (SERC) to establish a national Mass Spectrometry Center at Swansea University to provide an analytical service to British Universities. It was officially opened in April 1987 by Lord Callaghan. In 2002, the center was enlarged and the new laboratories were opened by Lord Morgan. Following successful £3,000,000 contract renewal Edwina Hart, the Minister for Economy, Science and Transport, officially re-opened the EPSRC National Research Facility after refurbishment in 2015.
Former Richmond player Kevin Sheedy started as head coach in 1981. Essendon reached the Grand Final in 1983, the first time since 1968. Hawthorn won by a then-record 83 points. In 1984, Essendon won the pre-season competition and completed the regular season on top of the ladder. The club played, and beat, Hawthorn in the 1984 VFL Grand Final to win their 13th premiership — their first since 1965. The teams met again in the 1985 Grand Final, which Essendon also won. At the start of 1986, Essendon were considered unbackable for three successive flags, but a succession of injuries to key players Paul Van der Haar (only fifteen games from 1986 to 1988), Tim Watson, Darren Williams, Roger Merrett and Simon Madden led the club to win only eight of its last eighteen games in 1986 and only nine games (plus a draw with Geelong) in 1987. In July 1987, the Bombers suffered a humiliation at the hands of Sydney, who fell two points short of scoring the then highest score in VFL history. In 1988, Essendon made a rebound to sixth place with twelve wins, including a 140-point thrashing of Brisbane in which they had a record sixteen individual goalkickers. In 1989, they rebounded further to second on the ladder with only five losses and thrashed Geelong in the Qualifying Final. However, after a fiery encounter with Hawthorn ended in a convincing defeat, the Bombers were eliminated by Geelong the following week. In 1990, Essendon finished top of the ladder.
Autoimmune metaplastic atrophic gastritis (AMAG) is an inherited form of atrophic gastritis characterized by an immune response directed toward parietal cells and intrinsic factor. Achlorhydria induces G cell (gastrin-producing) hyperplasia, which leads to hypergastrinemia. Gastrin exerts a trophic effect on enterochromaffin-like cells (ECL cells are responsible for histamine secretion) and is hypothesized to be one mechanism to explain the malignant transformation of ECL cells into carcinoid tumors in AMAG.
Sources: en.wikipedia.org
== Further reading == Park, Kun-Young; Cheigh, Hong-Sik (2003). Handbook of Vegetable Preservation and Processing. CRC Press. pp. 189–222. ISBN 978-0-8247-4301-7. Retrieved 18 May 2008. Gannon, Martin J. (2004). Understanding Global Cultures. SAGE Publications. pp. 123–130. ISBN 978-0-7619-2980-2. Retrieved 18 May 2008. kimchi. Park, Sung Hoon; Lee, Chang Hyeon (2023). "Evaluation of Accuracy and Adequacy of Kimchi Information in Major Foreign Online Encyclopedias". Journal of the Korean Society of Food Culture (in Korean). 38 (4): 203–216. doi:10.7318/KJFC/2023.38.4.203. ISSN 1225-7060.
The legislative election of 1957 was followed by several years of political stability that was accompanied by economic stagnation and curtailment of reforms and reformists. One of the last initiatives of the brief reform era was a nuclear weapons–free zone in Central Europe proposed in 1957 by Adam Rapacki, Poland's foreign minister. Culture in the Polish People's Republic, to varying degrees linked to the intelligentsia's opposition to the authoritarian system, developed to a sophisticated level under Gomułka and his successors. The creative process was often compromised by state censorship, but significant works were created in fields such as literature, theater, cinema and music, among others. Journalism of veiled understanding and varieties of native and Western popular culture were well represented. Uncensored information and works generated by émigré circles were conveyed through a variety of channels. The Paris-based Kultura magazine developed a conceptual framework for dealing with the issues of borders and the neighbors of a future free Poland, but for ordinary Poles Radio Free Europe was of foremost importance.
=== England === It has been argued by historians that, in the sixteenth century, England came to pursue a foreign policy which would preserve the equilibrium between Spain and France, which evolved into a balance-of-power policy:
In addition to non-viral delivery methods, RNA viruses have been engineered to achieve similar immunological responses. Typical RNA viruses used as vectors include retroviruses, lentiviruses, alphaviruses and rhabdoviruses, each of which can differ in structure and function. Clinical studies have utilized such viruses on a range of diseases in model animals such as mice, chicken and primates.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.